drugset
drugset / Trial / NCT05245058

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

NCT05245058 ↗

Phase 0 Recruiting 150 enrolled Shanghai Pharmaceuticals Holding Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors

Timeline

Start
2022-01-21
Primary completion
2026-12-21
Completion
2026-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject SPH5030 Small molecule 50 mg Oral
Subject SPH5030 Small molecule 100 mg Oral
Subject SPH5030 Small molecule 200 mg Oral
Subject SPH5030 Small molecule 300 mg Oral
Subject SPH5030 Small molecule 400 mg Oral

Indications

carcinoma